CoChat

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

Open access
Harbeck, Nadia, Ciruelos, Eva, Jerusalem, Guy, Müller, Volkmar, Niikura, Naoki, Viale, Giuseppe, Bartsch, Rupert, Kurzeder, Christian, Higgins, Michaela J., Connolly, Roisin M., Baron-Hay, Sally, Gión, María, Guarneri, Valentina, Bianchini, Giampaolo, Wildiers, Hans, Escrivá-de-Romaní, Santiago, Prahladan, Manoj, Bridge, Helen, Kuptsova-Clarkson, Nataliya, Scotto, Nana, Verma, Sunil, Lin, Nancy U., the DESTINY-Breast12 study group, Yeo, Belinda, McCarthy, Nicole, McCartney, Amelia, Clay, Timothy, Murray, Nicholas, Gombos, Andrea, Collignon, Joëlle, De Cuypere, Eveline, Jerzak, Katarzyna, Chia, Stephen, Maraldo, Maja, Rønlev, Jeanette, Brix, Eva, Tanner, Minna, Mattson, Johanna, Huovinen, Riikka, Wimberger, Pauline, Reinisch, Mattea, Tesch, Hans, Untch, Michael, Fasching, Peter, Park-Simon, Tjoung-Won, Tio, Joke, Braun, Michael, Grischke, Eva Maria, Marmé, Frederik, van Mackelenbergh, Marion, McCaffrey, John, De Laurentiis, Michelino, Caruso, Michele, Berardi, Rossana, Biganzoli, Laura, Fotia, Vittoria, Yamashita, Toshinari, Tsurutani, Junji, Tsugawa, Koichiro, Tomioka, Nobumoto, de Boer, Maaike, Houtsma, Daniel, Pilskog, Martin, Engebråten, Olav, Sætersdal, Anna, Wysocki, Piotr, Nowecki, Zbigniew, Radecka, Barbara, Jassem, Jacek, Duchnowska, Renata, Simões, Joana, Cardoso, Fatima, Sousa, Ana Rita, Losada, María Jesús Vidal, Manich, Cristina Saura, Gregori, Joaquin Gavilá, Marti, Maria Pilar Lopez, Borrego, Manuel Ruiz, Castán, Javier Cortés, López, Rafael López, Sanchez, César Rodríguez, Flores, Encarnación González, González, Carmen Hinojo, del Prado, Purificación Martínez, Schiza, Aglaia, Killander, Fredrika, Klint, Leif, Rossi, Lorenzo, Aebi, Stefan, Zaman, Khalil, Hall, Peter, Anders, Carey · 2024 · Nature Medicine
Cited by 227

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases (BMs). The phase 3b/4 DESTINY-Breast12 study investigated T-DXd in patients with HER2+ mBC and is, to our knowledge, the largest prospective study of T-DXd in patients with BMs in this setting. Patients (stable/active BMs (n = 263) and no BMs (n = 241)) treated with one or more prior anti-HER2–based regimens received T-DXd (5.4 mg per kg). Primary endpoints were progression-free survival (PFS; BMs cohort) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (non-BMs cohort). Additional endpoints included central nervous system (CNS) PFS, ORR, time to second progression, CNS ORR (BMs cohort), incidence of new symptomatic CNS metastases (non-BMs cohort), time to progression, duration of response, overall survival and safety (both cohorts). No formal hypothesis testing was conducted for this single-arm, open-label study. In the BMs cohort, 12-month PFS was 61.6% (95% confidence interval (CI): 54.9–67.6), and 12-month CNS PFS was 58.9% (95% CI: 51.9–65.3). In the non-BMs cohort, ORR was 62.7% (95% CI: 56.5–68.8). Grade 3 or higher adverse events occurred in 51% (BMs cohort) and 49% (non-BMs cohort) of patients. Investigator-reported interstitial lung disease/pneumonitis occurred in 16% (grade ≥3: 3%) of patients with BMs and 13% (grade ≥3: 1%) of patients without BMs. These data show substantial and durable overall and intracranial activity for T-DXd, supporting its use in previously treated patients with HER2+ mBC irrespective of stable/active baseline BMs. ClinicalTrials.gov identifier: NCT04739761.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03261-7

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., Baron-Hay, S., Gión, M., Guarneri, V., Bianchini, G., Wildiers, H., Escrivá-de-Romaní, S., Prahladan, M., Bridge, H., Kuptsova-Clarkson, N., Scotto, N., Verma, S., Lin, N. U., the DESTINY-Breast12 study group, Yeo, B., McCarthy, N., McCartney, A., Clay, T., Murray, N., Gombos, A., Collignon, J., De Cuypere, E., Jerzak, K., Chia, S., Maraldo, M., Rønlev, J., Brix, E., Tanner, M., Mattson, J., Huovinen, R., Wimberger, P., Reinisch, M., Tesch, H., Untch, M., Fasching, P., Park-Simon, T.-W., Tio, J., Braun, M., Grischke, E. M., Marmé, F., van Mackelenbergh, M., McCaffrey, J., De Laurentiis, M., Caruso, M., Berardi, R., Biganzoli, L., Fotia, V., Yamashita, T., Tsurutani, J., Tsugawa, K., Tomioka, N., de Boer, M., Houtsma, D., Pilskog, M., Engebråten, O., Sætersdal, A., Wysocki, P., Nowecki, Z., Radecka, B., Jassem, J., Duchnowska, R., Simões, J., Cardoso, F., Sousa, A. R., Losada, M. J. V., Manich, C. S., Gregori, J. G., Marti, M. P. L., Borrego, M. R., Castán, J. C., López, R. L., Sanchez, C. R., Flores, E. G., González, C. H., del Prado, P. M., Schiza, A., Killander, F., Klint, L., Rossi, L., Aebi, S., Zaman, K., Hall, P., & Anders, C.
Venue
Nature Medicine
Published
2024-09-13
Volume
30
Issue
12
Pages
3717-3727
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4402514945
Cited by
227
References
3
FWCI
34.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. https://app.cochat.ai/papers/10.1038/s41591-024-03261-7
The paper
Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., Baron-Hay, S., Gión, M., Guarneri, V., Bianchini, G., Wildiers, H., Escrivá-de-Romaní, S., Prahladan, M., Bridge, H., Kuptsova-Clarkson, N., . . . Anders, C. (2024). Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03261-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.